The offering constituting the private non-brokered placement of 15 Million units is only available to existing shareholders of the company, who as of the closing of business on May 16, 2022 hold common shares of Hemostemix
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.